CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
Eligible age
All ages
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To learn more about the long-term health in patients treated for B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Cluster of Differentiation antigen 19 (CD19) -redirected chimeric antigen receptor (CAR) T-cells. Primary Objective: To evaluate the feasibility of conducting standardized clinical assessments of pediatric, adolescent and young adult (AYA) B-ALL survivors post CD19-CAR T-cell therapy, treated at multiple institutions, leveraging the St Jude Lifetime Cohort (SJLIFE) clinical and research infrastructure. Exploratory Objectives: * To describe the prevalence of persistent and new/late-onset health conditions developing ≥2-years post CD19-CAR T-cell therapy in survivors of pediatric and AYA B-ALL. * To characterize neurocognitive and neurologic function in survivors ≥2-years post CD19- CAR T-cell therapy. * To characterize immune health in survivors ≥2-years post CD19-CAR T-cell therapy. * To characterize functional status in survivors ≥2-years post CD19-CAR T-cell therapy.
Sponsor: St. Jude Children's Research Hospital
You may qualify if…
- ✓ ≤ 26-years old at the time of the first CAR treatment
- ✓ Receipt of a CD19-containing CAR T-cell product (investigational or commercial) for B- ALL
- ✓ Receipt of one unique CAR product (reinfusion of same product allowed)
- ✓ Sustained remission without subsequent therapy post-CAR (exception= post-CAR consolidative HCT)
- ✓ Receipt of only one prior HCT (inclusive of pre- or post-CAR)
- ✓ ≥ 2-years post last CAR T-cell infusion
You may not qualify if…
- ✕ Inability or unwillingness of research participant or legal guardian/representative to give written informed consent
Where it's recruiting
Memphis
Source: ClinicalTrials.gov · NCT07048535 · last updated 2026-04-29